Abstract:Background: Proline-rich transmembrane protein 2 (PRRT2) plays an important role in the central nervous system and mutations in the gene are implicated in a variety of neurological disorders. This study aimed to summarize the clinical characteristics and gene expression analysis of neurological diseases related to the PRRT2 gene and explore the clinical characteristics, therapeutic effects, and possible pathogenic mechanisms of related diseases. Methods: We enrolled 10 children with PRRT2 mutation-related neurological diseases who visited the Children's Hospital affiliated with the Shanghai Jiaotong University School of Medicine/Shanghai Children's Hospital between May 2017 and February 2022. Video electroencephalography (VEEG), cranial imaging, treatment regimens, gene results, and gene expression were analyzed. Genetic testing involved targeted sequencing or whole-exome genome sequencing (WES). We further analyzed the expression and mutation conservation of PRRT2 and synaptosome-associated protein 25 (SNAP25) in blood samples using quantitative polymerase chain reaction (qPCR) and predicted the protein structure. Summary analysis of the reported gene maps and domains was also performed. Results: Ten children with PRRT2 gene mutations were analyzed, and 4 mutations were identified, consisting of 2 new (c.518A > C, p.Glu173 Ala; c.879 + 112G > A, p.?) and two known (c. 649 dup, p. Arg217Profs * 8; c. 649 del, p. Arg217Glufs * 12) mutations. Among these mutations, one was de novo (P6), and three could not be determined because one parent refused genetic testing. The clinical phenotypes were paroxysmal kinesigenic dyskinesia (PKD), benign familial infantile epilepsy (BFIE), epilepsy, infantile spasms, and intellectual disability. The qPCR results showed that PRRT2 gene expression levels were significantly lower in children and parent carriers than the control group. The SNAP25 gene expression level of affected children was significantly lower ( P ≤ 0.001) than that of the control group. The mutation sites reported in this study are highly conserved in different species. Among the various drugs used, oxcarbazepine and sodium valproate were the most effective. All 10 children had a good disease prognosis, and 8 were completely controlled with no recurrence, whereas 2 had less severe and fewer seizures. Conclusion: Mutation of PRRT2 led to a significant decrease in its protein expression level and that of SNAP25, suggesting that the mutant protein may lead to the loss of its function and that of related proteins. This mutation site is highly conserved in most species, and there was no significant correlation between specific PRRT2 genotypes and clinical phenotypes. Asymptomatic carriers also have decreased gene expression levels, suggesting that more factors are involved.

PRRT2 variants and effectiveness of various antiepileptic drugs in self-limited familial infantile epilepsy

Phenotypes and PRRT2 mutations in Chinese families with benign familial infantile epilepsy and infantile convulsions with paroxysmal choreoathetosis

Clinical characteristics and genetics of ten Chinese children with PRRT2-associated neurological diseases

Phenotypic Overlap among Paroxysmal Dyskinesia Subtypes: Lesson from a Family with PRRT2 Gene Mutation.

PRRT2 mutations in a cohort of Chinese families with paroxysmal kinesigenic dyskinesia and genotype-phenotype correlation reanalysis in literatures.

The Genotype and Phenotype of Proline-Rich Transmembrane Protein 2 Associated Disorders in Chinese Children

Phenotypes and PRRT2 mutation analysis in families with benign familial infantile epilepsy

Bi-allelic PRRT2 variants may predispose to Self-limited Familial Infantile Epilepsy

Clinical phenotypic and genotypic characterization of NPRL3-related epilepsy

Study of Pathogenic gene spectrum in benign familial infantile epilepsy

[Spectrum of Mutations in Benign Familial Neonatal-Infantile Epilepsy].

Novel PRRT2 Mutations in Paroxysmal Dyskinesia Patients with Variant Inheritance and Phenotypes

Outcomes Of Sustained-Release Formulation Of Valproate And Topiramate Monotherapy In Patients With Epilepsy: A Multi-Centre, Cohort Study

PRRT2 controls neuronal excitability by negatively modulating Na+ channel 1.2/1.6 activity

Penetrance Estimation of PRRT2 Variants in Paroxysmal Kinesigenic Dyskinesia and Infantile Convulsions

Genetic and phenotypic analyses of PRRT2 positive and negative paroxysmal kinesigenic dyskinesia

SCN2A-Related Epilepsy: the Phenotypic Spectrum, Treatment and Prognosis

The clinical features of familial focal epilepsy with variable foci and NPRL3 gene variant

Specific OCT1 and ABCG2 Polymorphisms Are Associated with Lamotrigine Concentrations in Chinese Patients with Epilepsy

Association of a Polymorphism in MDR1C3435T with Intractable Epilepsy of Children

Relationship between clinical features of intractable epilepsy in children and the single nucleotide polymorphisms of CYP3A41G